Literature DB >> 19385778

Opinions of IRB Members and Chairs Regarding Investigators' Relationships with Industry.

Joel S Weissman1, Greg Koski, Christine Vogeli, Carrie Thiessen, Eric G Campbell.   

Abstract

THE EFFECTS OF CONFLICTS OF INTEREST on the conduct of human research have been roundly debated, but less attention has been paid to the role of Institutional Review Boards (IRBs) in their identification and management. Government and private policy recommendations disagree about IRBs' responsibility in this area. A survey focusing on respondents' attitudes and behaviors regarding consideration of investigator and institutional financial relationships with industry when reviewing research protocols was mailed to a random sample of 893 IRB members and 316 IRB chairs at 115 academic institutions (response rates of 67% and 72%, respectively). More than half of IRB members and chairs felt that industry relationships posed a moderate or big problem for research integrity nationally, and about one-third thought such relationships were a problem at their own institution. Approximately two-thirds felt that investigator-industry relationships should be considered when reviewing protocols regardless of whether they are deemed to be conflicts of interest. While more than 90% of IRB members and chairs believed that investigators' relationships should be disclosed to research participants, 61% of members and chairs reported that these relationships were not always disclosed to participants. While more than 80% believed that institutional relationships should be disclosed to research participants, only 39% of members and chairs said this happened all the time. Some beliefs of IRB members and chairs are at odds with recommendations to limit the role of IRBs in the management of potential investigator conflicts. Lack of unambiguous guidelines has led to inconsistent practices among IRBs.

Entities:  

Year:  2008        PMID: 19385778     DOI: 10.1525/jer.2008.3.1.3

Source DB:  PubMed          Journal:  J Empir Res Hum Res Ethics        ISSN: 1556-2646            Impact factor:   1.742


  4 in total

1.  UNIVERSITY TRUSTEES AS CHANNELS BETWEEN ACADEME AND INDUSTRY: TOWARD AN UNDERSTANDING OF THE EXECUTIVE SCIENCE NETWORK.

Authors:  Charles Mathies; Sheila Slaughter
Journal:  Res Policy       Date:  2013

2.  Disclosure of financial relationships to participants in clinical research.

Authors:  Kevin P Weinfurt; Mark A Hall; Nancy M P King; Joëlle Y Friedman; Kevin A Schulman; Jeremy Sugarman
Journal:  N Engl J Med       Date:  2009-08-27       Impact factor: 91.245

3.  Investigator experiences with financial conflicts of interest in clinical trials.

Authors:  Paula A Rochon; Melanie Sekeres; John Hoey; Joel Lexchin; Lorraine E Ferris; David Moher; Wei Wu; Sunila R Kalkar; Marleen Van Laethem; Andrea Gruneir; Jennifer Gold; James Maskalyk; David L Streiner; Nathan Taback; An-Wen Chan
Journal:  Trials       Date:  2011-01-12       Impact factor: 2.279

4.  IRB Oversight of Patient-Centered Outcomes Research: A National Survey of IRB Chairpersons.

Authors:  Joel S Weissman; Eric G Campbell; I Glenn Cohen; Holly Fernandez Lynch; Emily A Largent; Avni Gupta; Ronen Rozenblum; Melissa Abraham; Karen Spikes; Maureen Fagan; Martie Carnie
Journal:  J Empir Res Hum Res Ethics       Date:  2018-06-14       Impact factor: 1.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.